Physician profile
Sridhar Jatla
NPI 1891704565
$10,053.53
in general payments reported to CMS, 2019-2025
61 companies · $2,132 in 2025
The $2,132 reported for 2025 was more than what 81% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $1,080 · 2021: $971 · 2022: $1,583 · 2023: $1,784 · 2024: $1,428 · 2025: $2,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,050 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,050.45 |
| Education | $293.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $1,653.37 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $1,431.35 | 2019-2025 | Xywav, Epidiolex |
| Avadel Cns Pharmaceuticals, LLC | $852.35 | 2023-2025 | Lumryz |
| Teva Pharmaceuticals USA, INC. | $636.02 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Axsome Therapeutics, INC. | $489.93 | 2022-2025 | Sunosi |
| Abbvie INC. | $468.42 | 2021-2025 | |
| Lilly USA, LLC | $401.65 | 2019-2025 | Kisunla, Zepbound, Emgality |
| Merck Sharp & Dohme LLC | $384.74 | 2019-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $384.52 | 2019-2025 | Ponvory |
| Eisai INC. | $315.56 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $266.05 | 2019-2024 | Ingrezza |
| Ucb, INC. | $252.60 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Supernus Pharmaceuticals, INC. | $248.98 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $190.10 | 2022-2024 | Quviviq |
| Acadia Pharmaceuticals INC | $160.45 | 2021-2025 | Daybue, Nuplazid |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sridhar Jatla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.